Global and China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, Status and Forecast 2020-2026
Table of Contents1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 ACH-4471
1.2.3 ALN-CC5
1.2.4 ALXN-1210
1.2.5 AMY-101
1.2.6 APL-2
1.2.7 Others
1.3 Market by Application
1.3.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application: 2020 VS 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Perspective (2015-2026)
2.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Growth Trends by Regions
2.2.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Market Size
3.1.1 Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Revenue (2015-2020)
3.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Players (2015-2020)
3.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue
3.4 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio
3.4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in 2019
3.5 Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Area Served
3.6 Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Product Solution and Service
3.7 Date of Enter into Paroxysmal Nocturnal Hemoglobinuria Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Type (2015-2026)
4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Type (2015-2020)
4.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Type (2021-2026)
5 Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Application (2015-2026)
5.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Historic Market Size by Application (2015-2020)
5.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2015-2026)
6.2 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020)
6.3 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020)
6.4 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2015-2026)
7.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020)
7.3 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020)
7.4 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2015-2026)
8.2 China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020)
8.3 China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020)
8.4 China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2015-2026)
9.2 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020)
9.3 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020)
9.4 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (2015-2026)
10.2 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020)
10.3 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020)
10.4 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
11.1 Achillion Pharmaceuticals Inc
11.1.1 Achillion Pharmaceuticals Inc Company Details
11.1.2 Achillion Pharmaceuticals Inc Business Overview
11.1.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.1.4 Achillion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020))
11.1.5 Achillion Pharmaceuticals Inc Recent Development
11.2 Akari Therapeutics Plc
11.2.1 Akari Therapeutics Plc Company Details
11.2.2 Akari Therapeutics Plc Business Overview
11.2.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.2.4 Akari Therapeutics Plc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
11.2.5 Akari Therapeutics Plc Recent Development
11.3 Alexion Pharmaceuticals Inc
11.3.1 Alexion Pharmaceuticals Inc Company Details
11.3.2 Alexion Pharmaceuticals Inc Business Overview
11.3.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.3.4 Alexion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
11.3.5 Alexion Pharmaceuticals Inc Recent Development
11.4 Alnylam Pharmaceuticals Inc
11.4.1 Alnylam Pharmaceuticals Inc Company Details
11.4.2 Alnylam Pharmaceuticals Inc Business Overview
11.4.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.4.4 Alnylam Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
11.4.5 Alnylam Pharmaceuticals Inc Recent Development
11.5 Amgen Inc
11.5.1 Amgen Inc Company Details
11.5.2 Amgen Inc Business Overview
11.5.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.5.4 Amgen Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
11.5.5 Amgen Inc Recent Development
11.6 Apellis Pharmaceuticals Inc
11.6.1 Apellis Pharmaceuticals Inc Company Details
11.6.2 Apellis Pharmaceuticals Inc Business Overview
11.6.3 Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.6.4 Apellis Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
11.6.5 Apellis Pharmaceuticals Inc Recent Development
11.7 F. Hoffmann-La Roche Ltd
11.7.1 F. Hoffmann-La Roche Ltd Company Details
11.7.2 F. Hoffmann-La Roche Ltd Business Overview
11.7.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.7.4 F. Hoffmann-La Roche Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
11.7.5 F. Hoffmann-La Roche Ltd Recent Development
11.8 ISU ABXIS Co Ltd
11.8.1 ISU ABXIS Co Ltd Company Details
11.8.2 ISU ABXIS Co Ltd Business Overview
11.8.3 ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.8.4 ISU ABXIS Co Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
11.8.5 ISU ABXIS Co Ltd Recent Development
11.9 Novartis AG
11.9.1 Novartis AG Company Details
11.9.2 Novartis AG Business Overview
11.9.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.9.4 Novartis AG Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
11.9.5 Novartis AG Recent Development
11.10 NovelMed Therapeutics Inc
11.10.1 NovelMed Therapeutics Inc Company Details
11.10.2 NovelMed Therapeutics Inc Business Overview
11.10.3 NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
11.10.4 NovelMed Therapeutics Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
11.10.5 NovelMed Therapeutics Inc Recent Development
11.11 Omeros Corp
10.11.1 Omeros Corp Company Details
10.11.2 Omeros Corp Business Overview
10.11.3 Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
10.11.4 Omeros Corp Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
10.11.5 Omeros Corp Recent Development
11.12 Ra Pharmaceuticals Inc
10.12.1 Ra Pharmaceuticals Inc Company Details
10.12.2 Ra Pharmaceuticals Inc Business Overview
10.12.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
10.12.4 Ra Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
10.12.5 Ra Pharmaceuticals Inc Recent Development
11.13 Regeneron Pharmaceuticals Inc
10.13.1 Regeneron Pharmaceuticals Inc Company Details
10.13.2 Regeneron Pharmaceuticals Inc Business Overview
10.13.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
10.13.4 Regeneron Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
10.13.5 Regeneron Pharmaceuticals Inc Recent Development
11.14 Regenesance BV
10.14.1 Regenesance BV Company Details
10.14.2 Regenesance BV Business Overview
10.14.3 Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
10.14.4 Regenesance BV Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
10.14.5 Regenesance BV Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesTable 1. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 3. Key Players of ACH-4471
Table 4. Key Players of ALN-CC5
Table 5. Key Players of ALXN-1210
Table 6. Key Players of AMY-101
Table 7. Key Players of APL-2
Table 8. Key Players of Others
Table 9. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Regions (2015-2020)
Table 13. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Regions (2021-2026)
Table 15. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Market Trends
Table 16. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Drivers
Table 17. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Challenges
Table 18. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Restraints
Table 19. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Players (2015-2020) (US$ Million)
Table 20. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Players (2015-2020)
Table 21. Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment as of 2019)
Table 22. Global Paroxysmal Nocturnal Hemoglobinuria Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Paroxysmal Nocturnal Hemoglobinuria Treatment Product Solution and Service
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020) (US$ Million)
Table 27. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Share by Type (2015-2020)
Table 28. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Type (2021-2026)
Table 29. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Share by Application (2015-2020)
Table 30. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020) (US$ Million)
Table 31. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Share by Application (2021-2026)
Table 32. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020) (US$ Million)
Table 33. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type (2015-2020)
Table 34. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020) (US$ Million)
Table 35. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application (2015-2020)
Table 36. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (US$ Million) (2015-2020)
Table 37. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2015-2020)
Table 38. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020) (US$ Million)
Table 39. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type (2015-2020)
Table 40. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020) (US$ Million)
Table 41. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application (2015-2020)
Table 42. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (US$ Million) (2015-2020)
Table 43. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2015-2020)
Table 44. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020) (US$ Million)
Table 45. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type (2015-2020)
Table 46. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020) (US$ Million)
Table 47. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application (2015-2020)
Table 48. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (US$ Million) (2015-2020)
Table 49. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Region (2015-2020)
Table 50. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020) (US$ Million)
Table 51. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type (2015-2020)
Table 52. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020) (US$ Million)
Table 53. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application (2015-2020)
Table 54. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (US$ Million) (2015-2020)
Table 55. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2015-2020)
Table 56. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2015-2020) (US$ Million)
Table 57. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type (2015-2020)
Table 58. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2015-2020) (US$ Million)
Table 59. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application (2015-2020)
Table 60. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country (US$ Million) (2015-2020)
Table 61. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Country (2015-2020)
Table 62. Achillion Pharmaceuticals Inc Company Details
Table 63. Achillion Pharmaceuticals Inc Business Overview
Table 64. Achillion Pharmaceuticals Inc Product
Table 65. Achillion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (US$ Million)
Table 66. Achillion Pharmaceuticals Inc Recent Development
Table 67. Akari Therapeutics Plc Company Details
Table 68. Akari Therapeutics Plc Business Overview
Table 69. Akari Therapeutics Plc Product
Table 70. Akari Therapeutics Plc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (US$ Million)
Table 71. Akari Therapeutics Plc Recent Development
Table 72. Alexion Pharmaceuticals Inc Company Details
Table 73. Alexion Pharmaceuticals Inc Business Overview
Table 74. Alexion Pharmaceuticals Inc Product
Table 75. Alexion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (US$ Million)
Table 76. Alexion Pharmaceuticals Inc Recent Development
Table 77. Alnylam Pharmaceuticals Inc Company Details
Table 78. Alnylam Pharmaceuticals Inc Business Overview
Table 79. Alnylam Pharmaceuticals Inc Product
Table 80. Alnylam Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (US$ Million)
Table 81. Alnylam Pharmaceuticals Inc Recent Development
Table 82. Amgen Inc Company Details
Table 83. Amgen Inc Business Overview
Table 84. Amgen Inc Product
Table 85. Amgen Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (US$ Million)
Table 86. Amgen Inc Recent Development
Table 87. Apellis Pharmaceuticals Inc Company Details
Table 88. Apellis Pharmaceuticals Inc Business Overview
Table 89. Apellis Pharmaceuticals Inc Product
Table 90. Apellis Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (US$ Million)
Table 91. Apellis Pharmaceuticals Inc Recent Development
Table 92. F. Hoffmann-La Roche Ltd Company Details
Table 93. F. Hoffmann-La Roche Ltd Business Overview
Table 94. F. Hoffmann-La Roche Ltd Product
Table 95. F. Hoffmann-La Roche Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (US$ Million)
Table 96. F. Hoffmann-La Roche Ltd Recent Development
Table 97. ISU ABXIS Co Ltd Business Overview
Table 98. ISU ABXIS Co Ltd Product
Table 99. ISU ABXIS Co Ltd Company Details
Table 100. ISU ABXIS Co Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (US$ Million)
Table 101. ISU ABXIS Co Ltd Recent Development
Table 102. Novartis AG Company Details
Table 103. Novartis AG Business Overview
Table 104. Novartis AG Product
Table 105. Novartis AG Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (US$ Million)
Table 106. Novartis AG Recent Development
Table 107. NovelMed Therapeutics Inc Company Details
Table 108. NovelMed Therapeutics Inc Business Overview
Table 109. NovelMed Therapeutics Inc Product
Table 110. NovelMed Therapeutics Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (US$ Million)
Table 111. NovelMed Therapeutics Inc Recent Development
Table 112. Omeros Corp Company Details
Table 113. Omeros Corp Business Overview
Table 114. Omeros Corp Product
Table 115. Omeros Corp Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (US$ Million)
Table 116. Omeros Corp Recent Development
Table 117. Ra Pharmaceuticals Inc Company Details
Table 118. Ra Pharmaceuticals Inc Business Overview
Table 119. Ra Pharmaceuticals Inc Product
Table 120. Ra Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (US$ Million)
Table 121. Ra Pharmaceuticals Inc Recent Development
Table 122. Regeneron Pharmaceuticals Inc Company Details
Table 123. Regeneron Pharmaceuticals Inc Business Overview
Table 124. Regeneron Pharmaceuticals Inc Product
Table 125. Regeneron Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (US$ Million)
Table 126. Regeneron Pharmaceuticals Inc Recent Development
Table 127. Regenesance BV Company Details
Table 128. Regenesance BV Business Overview
Table 129. Regenesance BV Product
Table 130. Regenesance BV Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020) (US$ Million)
Table 131. Regenesance BV Recent Development
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
List of FiguresFigure 1. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Type: 2020 VS 2026
Figure 2. ACH-4471 Features
Figure 3. ALN-CC5 Features
Figure 4. ALXN-1210 Features
Figure 5. AMY-101 Features
Figure 6. APL-2 Features
Figure 7. Others Features
Figure 8. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application: 2020 VS 2026
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Others Case Studies
Figure 12. Paroxysmal Nocturnal Hemoglobinuria Treatment Report Years Considered
Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size (US$ Million), YoY Growth 2015-2026
Figure 14. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Regions: 2020 VS 2026
Figure 15. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Regions (2021-2026)
Figure 16. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Players in 2019
Figure 17. Global Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in 2019
Figure 19. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 20. United States Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 21. Canada Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 22. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 23. Germany Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 24. France Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 25. U.K. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 26. Italy Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 27. Russia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 28. Nordic Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 29. Rest of Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 30. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 31. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 32. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 33. South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 34. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 35. India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 36. Australia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 37. Rest of Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 38. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 39. Mexico Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 40. Brazil Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 41. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 42. Turkey Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 43. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 44. UAE Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 45. Rest of Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 46. Achillion Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 47. Akari Therapeutics Plc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 48. Alexion Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 49. Alnylam Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 50. Amgen Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 51. Apellis Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 52. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 53. ISU ABXIS Co Ltd Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 54. Novartis AG Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 55. NovelMed Therapeutics Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 56. Omeros Corp Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 57. Ra Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 58. Regeneron Pharmaceuticals Inc Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 59. Regenesance BV Revenue Growth Rate in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2015-2020)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed